Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus

Journal of Innate Immunity

Volumn 2, Issue 6, 2010, Pages 587-595

  Pence, Morgan A ^a,b   Rooijakkers, Suzan H M ^b,h   Cogen, Anna L ^c   Cole, Jason N ^b,g   Hollands, Andrew ^b,g   Gallo, Richard L ^b,c,f   Nizet, Victor ^b,d,e  

^a Biomedical Sciences Graduate Program   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e RADY CHILDREN'S HOSPITAL   (United States)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^g UNIVERSITY OF WOLLONGONG   (Australia)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antimicrobial peptides; Cathelicidin; Complement system; Innate immunity; Streptococcus; Virulence factors

Indexed keywords

CATHELICIDIN; MEMBRANE PROTEIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BLOOD; CELL SURVIVAL; COMPLEMENT INHIBITION; FEMALE; GENOME; HUMAN; IMMUNITY; IN VIVO STUDY; INNATE IMMUNITY; MACROPHAGE; MALE; MOUSE; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STREPTOCOCCUS GROUP A; WILD TYPE;

ANIMALS; BACTERIAL PROTEINS; BACTERIOLYSIS; CATHELICIDINS; CELL GROWTH PROCESSES; CELLS, CULTURED; CLONING, MOLECULAR; GENE EXPRESSION REGULATION, BACTERIAL; GENE KNOCKOUT TECHNIQUES; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MUTATION; PROTEIN BINDING; SPECIES SPECIFICITY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TRANSGENES; VIRULENCE;

EID: 77958182535     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000317672     Document Type: Article

References (31)

1. Chatellier S, Ihendyane N, Kansal RG, Khambaty F, Basma H, Norrby-Teglund A, Low DE, McGeer A, Kotb M: Genetic relatedness and superantigen expression in group A Streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect Immun 2000;68:3523-3534.
2. Cleary PP, LaPenta D, Vessela R, Lam H, Cue D: A globally-disseminated M1 subclone of group A streptococci differs from other subclones by 70 kilobases of prophage DNA and capacity for high-frequency intracellular invasion. Infect Immun 1998;66:5592-5597.
3. Cockerill FR 3rd, MacDonald KL, Thompson RL, Roberson F, Kohner PC, Besser-Wiek J, Manahan JM, Musser JM, Schlievert PM, Talbot J, Frankfort B, Steckelberg JM, Wilson WR, Osterholm MT: An outbreak of invasive group A streptococcal disease associated with high carr iage rates of the invasive clone among school-aged children. JAMA 1997;277:38-43.
4. Aziz RK, Kotb M: Rise and persistence of global M1T1 clone of Streptococcus pyogenes. Emerg Infect Dis 2008;14:1511-1517.
5. Carapetis JR, Steer AC, Mulholland EK, Weber M: The global burden of group A streptococcal diseases. Lancet Infect Dis 2005;5:685-694.
6. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM: Genome-wide analysis of group A streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog 2006;2:41-49.
7. Graham MR, Smoot LM, Migliaccio CA, Virtaneva K, Sturdevant DE, Porcella SF, Federle MJ, Adams GJ, Scott JR, Musser JM: Virulence control in group A Streptococcus by a two-component gene regulatory system: global expression profiling and in vivo infection modeling. Proc Natl Acad Sci USA 2002;99:13855-13860.
8. Engleberg NC, Heath A, Miller A, Rivera C, DiRita VJ: Spontaneous mutations in the Csr RS two-component regulatory system of Streptococcus pyogenes result in enhanced virulence in a murine model of skin and soft tissue infection. J Infect Dis 2001;183:1043-1054.
9. Raeder R, Harokopakis E, Hollingshead S, Boyle MD: Absence of SpeB production in virulent large capsular forms of group A streptococcal strain 64. Infect Immun 2000;68:744-751.
10. Aziz RK, Pabst MJ, Jeng A, Kansal R, Low DE, Nizet V, Kotb M: Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of multiple virulence factors by SpeB. Mol Microbiol 2004;51:123-134.
11. Cole JN, McArthur JD, McKay FC, Sanderson-Smith ML, Cork AJ, Ranson M, Rohde M, Itzek A, Sun H, Ginsburg D, Kotb M, Nizet V, Chhatwal GS, Walker MJ: Trigger for group A streptococcal M1T 1 invasive disease. FASEB J 2006;20:1745-1747.
12. Akesson P, Sjöholm AG, Björck L: Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function. J Biol Chem 1996;271:1081-1088.
13. Fernie-King BA, Seilly DJ, Willers C, Wurzner R, Davies A, Lachmann PJ: Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology 2001;103:390-398.
14. Hartas J, Sriprakash KS: Streptococcus pyogenes strains containing emm12 and emm55 possess a novel gene coding for distantly related sic protein. Microb Pathog 1999;26:25-33.
15. Hoe NP, Vuopio-Varkila J, Vaara M, Grigsby D, De Lorenzo D, Fu YX, Dou SJ, Pan X, Nakashima K, Musser JM: Distribution of streptococcal inhibitor of complement variants in pharyngitis and invasive isolates in an epidemic of serotype M1 group A Streptococcus infection. J Infect Dis 2001;183:633-639.
16. Frick IM, Akesson P, Rasmussen M, Schmidtchen A, Björck L: SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J Biol Chem 2003;278:16561-16566.
17. Fernie-King BA, Seilly DJ, Davies A, Lachmann PJ: Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme. Infect Immun 2002;70:4908-4916.
18. Fernie-King BA, Seilly DJ, Lachmann PJ: The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human β defensins. Immunology 2004;111:444-452.
19. Hoe NP, Ireland RM, DeLeo FR, Gowen BB, Dorward DW, Voyich JM, Liu M, Burns EH Jr, Culnan DM, Bretscher A, Musser JM: Insight into the molecular basis of pathogen abundance: group A Streptococcus inhibitor of complement inhibits bacterial adherence and internalization into human cells. Proc Natl Acad Sci USA 2002;99:7646-7651.
20. Lukomski S, Hoe NP, Abdi I, Rurangirwa J, Kordari P, Liu M, Dou SJ, Adams GG, Musser JM: Nonpolar inactivation of the hypervariable streptococcal inhibitor of complement gene (SIC) in serotype M1 Streptococcus pyogenes significantly decreases mouse mucosal colonization. Infect Immun 2000;68:535-542.
21. Walker MJ, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, Henningham A, McArthur JD, Dinkla K, Aziz RK, Kansal RG, Simpson AJ, Buchanan JT, Chhatwal GS, Kotb M, Nizet V: DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med 2007;13:981-985.
22. Jeng A, Sakota V, Li Z, Datta V, Beall B, Nizet V: Molecular genetic analysis of a group A Streptococcus operon encoding serum opacity factor and a novel fibronectin-binding protein, Sfbx. J Bacteriol 2003;185:1208-1217.
23. Simon D, Ferretti JJ: Electrotransformation of Streptococcus pyogenes with plasmid and linear DNA. FEMS Microbiol Lett 1991;66:219-224.
24. Collin M, Olsén A: Generation of a mature streptococcal cysteine proteinase is dependent on cell wall-anchored M1 protein. Mol Microbiol 2000;36:1306-1318.
25. Hoe NP, Kordari P, Cole R, Liu M, Palzkill T, Huang W, McLellan D, Adams CJ, Hu M, Vuopio-Varkila J, Cate TR, Pichichero ME, Edwards KM, Eskola J, Low DE, Musser JM: Human immune response to streptococcal inhibitor of complement, a serotype M1 group A Streptococcus extracellular protein involved in epidemics. J Infect Dis 2000;182:1425-1436.
26. Johansson L, Thulin P, Sendi P, Hertzén E, Linder A, Akesson P, Low DE, Agerberth B, Norrby-Teglund A: Cathelicidin LL-37 in severe Streptococcus pyogenes soft tissue infections in humans. Infect Immun 2008;76:3399-3404.
27. Lauth X, von Köckritz-Blickwede M, McNamara CW, Myskowski S, Zinkernagel AS, Beall B, Ghosh P, Gallo RL, Nizet V: M1 protein allows group A streptococcal survival in phagocyte extracellular traps through cathelicidin inhibition. J Innate Immun 2009;1:202-214.
28. Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, Pestonjamasp V, Piraino J, Huttner K, Gallo RL: Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001;414:454-457.
29. Ravins M, Jaffe J, Hanski E, Shetzigovski I, Natanson-Yaron S, Moses AE: Characterization of a mouse-passaged, highly encapsulated variant of group A Streptococcus in in vitro and in vivo studies. J Infect Dis 2000;182:1702-1711.
30. Lai Y, Gallo RL: AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009;30:131-141.
31. Radek K, Gallo RL: Antimicrobial peptides: natural effectors of the innate immune system. Semin Immunopathol 2007;29:27-43.